An economic evaluation of early assessment for Alzheimer's disease in the United Kingdom

United BioSource Corporation, Lexington, MA, USA.
Alzheimer's & dementia: the journal of the Alzheimer's Association (Impact Factor: 12.41). 03/2011; 8(1):22-30. DOI: 10.1016/j.jalz.2010.07.001
Source: PubMed


Diagnosing and treating patients with Alzheimer's disease (AD) at an early stage should improve the quality of life of the patient and caregiver. In the United Kingdom, cost-effectiveness of early assessment of individuals presenting with subjective memory complaints and treating those with AD with donepezil was evaluated.
A discrete event simulation of AD progression and the effect of treatment interventions was developed. Patient-level data from donepezil trials and a 7-year follow-up registry were used to model correlated longitudinal rates of change in cognition, behavior, and function. Other epidemiological and health services data, including estimates of undiagnosed dementia and delays in diagnosis, were based on published sources. Simulated individuals were followed up for 10 years.
In the base-case estimates, 17 patients need to be assessed to diagnose one patient with AD, resulting in an average assessment cost of £4100 ($6000; $1 US = £0.68 UK) per patient diagnosed (2007 cost year). In comparison with a scenario without early assessment or pharmacologic treatment, early assessment reduces health care costs by £3600 ($5300) per patient and societal costs by £7750 ($11,400). Savings are also substantial compared with treatment without early assessment, averaging £2100 ($3100) in health care costs, and £5700 ($8400) in societal costs. Results are most sensitive to estimates of patient care costs and the probability of patients reporting subjective memory complaints. In probabilistic sensitivity analysis, early assessment leads to savings or is highly cost-effective in the majority of cases.
Although early assessment has significant up-front costs, identifying AD patients at an early stage results in cost savings and health benefits compared with no treatment or treatment in the absence of early assessment.

Download full-text


Available from: Luis Hernandez, Oct 31, 2014
79 Reads
  • Source
    • "Reassuringly, nearly 50% of the AD cohort was prescribed an AChE inhibitor within 1 year of diagnosis, adhering to the 2012 NICE treatment guidelines recommending treatment for patients with both mild and moderate to severe AD [8]. While it is unclear at this time whether earlier diagnosis of AD would subsequently decrease the burden on the health care system, there is evidence that early AD diagnosis decreases subsequent primary health care medical costs [30]. Our study did not address the timing of AD diagnosis as a factor in the health care resource burden on primary care. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background This study examined medical resource utilisation patterns in the United Kingdom (UK) prior to and following Alzheimer’s disease (AD) diagnosis. Methods A patient cohort aged 65 years and older with newly diagnosed AD between January 2008 and December 2010 was identified through the UK’s Clinical Practice Research Datalink (CPRD). Patients with a continuous record in the CPRD (formerly the General Practice Research Database [GPRD]) for both the 3 years prior to, and the 1 year following, AD diagnosis were eligible for inclusion. A control cohort was identified by matching general older adult (GOA) patients to patients with AD based on year of birth, gender, region, and Charlson Comorbidity Index at a ratio of 2:1. Medical resource utilisation was calculated in 6-month intervals over the 4-year study period. Comparisons between AD and GOA control cohorts were conducted using conditional logistic regression for patient characteristics and a generalised linear model for resource utilisation. Results Data for the AD cohort (N = 3,896) and matched GOA control cohort (N = 7,792) were extracted from the CPRD. The groups were 65% female and the AD cohort had a mean age of 79.9 years (standard deviation 6.5 years) at the date of diagnosis. Over the entire study period, the AD cohort had a significantly higher mean primary care consultation rate than the GOA cohort (p < .0001). While the GOA cohort primary care consultation rate gradually increased over the 4-year period (ranging from 5 to 7 consultations per 6-month period), increases were more pronounced in the AD cohort (ranging from 6 to 11 consultations per 6-month period, peaking during the 6-month periods immediately prior to and post diagnosis). The AD cohort also had a higher overall specialty referral rate than the GOA cohort over the 4-year period (37% vs. 25%, respectively; p < .0001); the largest difference was during the 6 months immediately prior to AD diagnosis (17% vs. 5%, respectively; p < .0001). Conclusions In the UK, AD diagnosis is associated with significant increases in primary and secondary care resource utilisation, continuing beyond diagnosis. This evidence may be important to health care commissioners to facilitate effective mobilisation of appropriate AD-related health care resources.
    BMC Geriatrics 06/2014; 14(1):76. DOI:10.1186/1471-2318-14-76 · 1.68 Impact Factor
  • Source
    • "Although the debate over cost-effectiveness of current treatment is controversial, some economic studies have estimated that timely treatment is cost-effective [14]. A UK study based on 2007 costs estimated that over ten years, timely detection and treatment produced savings of £3600 (US $5508) in direct costs and an additional £4150 ($6350) in indirect costs (caregiver time) per patient [15]. Similar cost-effectiveness has been established for other healthcare systems, including the US [16]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Intervention and treatment in Alzheimer’s disease dementia (AD-dementia) can be cost effective but the majority of patients are not diagnosed in a timely manner. Technology is now available that can enable the earlier detection of cognitive loss associated with incipient dementia, offering the potential for earlier intervention in the UK health care system. This study aimed to determine to what extent the timing of an intervention affects its cost-effectiveness. Methods Using published data describing cognitive decline in the years prior to an AD diagnosis, we modelled the effects on healthcare costs and quality-adjusted life years of hypothetical symptomatic and disease-modifying interventions. Early and standard interventions were assumed to have equal clinical effects, but the early intervention could be applied up to eight years prior to standard diagnosis. Results A symptomatic treatment which immediately improved cognition by one MMSE point and reduced in efficacy over three years, would produce a maximum net benefit when applied at the earliest timepoint considered, i.e. eight years prior to standard diagnosis. In this scenario, the net benefit was reduced by around 17% for every year that intervention was delayed. In contrast, for a disease-modifying intervention which halted cognitive decline for one year, economic benefits would peak when treatment effects were applied two years prior to standard diagnosis. In these models, the maximum net benefit of the disease modifying intervention was fifteen times larger than that of the symptomatic treatment. Conclusion Timeliness of intervention is likely to have an important impact on the cost-effectiveness of both current and future treatments. Healthcare policy should aim to optimise the timing of AD-dementia diagnosis, which is likely to necessitate detecting and treating patients several years prior to current clinical practice.
    BMC Neurology 05/2014; 14(1):101. DOI:10.1186/1471-2377-14-101 · 2.04 Impact Factor
  • Source
    • "This modelling technique was selected mainly due to its capability to track events experienced by patients over the course of simulation and to use them, along with other relevant patient and disease characteristics, to predict the course of disease progression over time. This feature, along with other advantages, has led to increasing use of DES in assessing the cost effectiveness of treatments in patients with AD [7] [25] [26]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The growing understanding of the use of biomarkers in Alzheimer's disease (AD) may enable physicians to make more accurate and timely diagnoses. Florbetaben, a beta-amyloid tracer used with positron emission tomography (PET), is one of these diagnostic biomarkers. This analysis was undertaken to explore the potential value of florbetaben PET in the diagnosis of AD among patients with suspected dementia and to identify key data that are needed to further substantiate its value. A discrete event simulation was developed to conduct exploratory analyses from both US payer and societal perspectives. The model simulates the lifetime course of disease progression for individuals, evaluating the impact of their patient management from initial diagnostic work-up to final diagnosis. Model inputs were obtained from specific analyses of a large longitudinal dataset from the New England Veterans Healthcare System and supplemented with data from public data sources and assumptions. The analyses indicate that florbetaben PET has the potential to improve patient outcomes and reduce costs under certain scenarios. Key data on the use of florbetaben PET, such as its influence on time to confirmation of final diagnosis, treatment uptake, and treatment persistency, are unavailable and would be required to confirm its value.
    International Journal of Alzheimer's Disease 12/2012; 2012:548157. DOI:10.1155/2012/548157
Show more

Similar Publications